EHMT2 and acute lymphoblastic leukemia: These data credential EHMT2 as a candidate therapeutic target in T-ALL and demonstrate that UNC0642 reduces T-ALL growth in xenograft models supporting further preclinical optimization of G9a inhibitors and evaluation in additional T-ALL models.